Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05822752
Title Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Acronym LIVIGNO-1
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP


No variant requirements are available.